PGNX Progenics Pharmaceuticals Inc.

5.07
-0.08  -2%
Previous Close 5.15
Open 5.17
Price To Book 6.04
Market Cap 449,311,679
Shares 88,621,633
Volume 681,721
Short Ratio
Av. Daily Volume 1,409,698
Stock charts supplied by TradingView

NewsSee all news

  1. Progenics Sends Letter to Shareholders

    Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders

  2. Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement

    Believes a Reconstituted Board is Immediately Needed to Reverse Strategic, Operational and Oversight Failures at the Company Urges Stockholders to Continue to Make their Voices Heard Following 2019 Annual Meeting

  3. PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus

  4. Velan Comments on Announced Sale of Progenics to Lantheus

    Believes Company's Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics' Potential Value Under

  5. Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PGNX

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus Holdings, Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 completion of enrolment announced August 5, 2019 with data due by end of 2019.
PyL
Prostate cancer
FDA approval announced July 30, 2018.
Azedra
Pheochromocytoma
Phase 3 trial met one of two co-primary endpoints.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 2 initiation of dosing announced June 13, 2019.
1095
Prostate Cancer

Latest News

  1. Progenics Sends Letter to Shareholders

    Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders

  2. Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement

    Believes a Reconstituted Board is Immediately Needed to Reverse Strategic, Operational and Oversight Failures at the Company Urges Stockholders to Continue to Make their Voices Heard Following 2019 Annual Meeting

  3. PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus

  4. Velan Comments on Announced Sale of Progenics to Lantheus

    Believes Company's Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics' Potential Value Under

  5. Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PGNX

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus Holdings, Inc.

  6. Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

    Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus' Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the

  7. Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution

    Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders No Shareholder Action Required at this Time NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,

  8. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current

  9. Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,